Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal sprayMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episo ...